3-乙基-5,6,7,8-四氢-喹啉 | 28971-02-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 3-乙基-5,6,7,8-四氢-喹啉
• 英文名称: 3-ethyl-5,6,7,8-tetrahydro-quinoline
• 英文别名: 3-Aethyl-5,6,7,8-tetrahydro-chinolin；3-Ethyl-5,6,7,8-tetrahydrochinolin；3-Ethyl-5,6,7,8-tetrahydroquinoline
• CAS: 28971-02-0
• 化学式: C₁₁H₁₅N
• 分子量: 161.247
• InChiKey: DTEHQVYSQJDEOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 镍 、 异丙醇 作用下， 生成 3-乙基-5,6,7,8-四氢-喹啉
  参考文献：
  名称：

  阮内镍作为有机氧化还原催化剂。

  摘要：

  DOI：

  10.1021/jo01161a022

文献信息

• HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITORS
  申请人：Ganguly A.K.

  公开号：US20110112068A1

  公开（公告）日：2011-05-12

  The described invention relates to novel human immunodeficiency virus protease inhibitors, pharmaceutical compositions containing at least one such inhibitor, methods of preparing such inhibitors, and methods of utilizing such inhibitors to treat HIV and HIV-related disorders.

  所描述的发明涉及新型人类免疫缺陷病毒蛋白酶抑制剂，包含至少一种此类抑制剂的药物组合物，制备此类抑制剂的方法，以及利用此类抑制剂治疗艾滋病毒及艾滋病毒相关疾病的方法。
• [EN] TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-a SYNTHESIS AND AS PDE4 INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE LA SYNTHÈSE DE TNF-? ET EN TANT QU'INHIBITEURS DE PDE4
  申请人：HIGH POINT PHARMACEUTICALS LLC

  公开号：WO2009094528A1

  公开（公告）日：2009-07-30

  The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-alpha or by PDE4, including but not limited to rheumatoid arthritis.

  本发明涉及化合物的化学式（I），如本文所定义，药物组合物以及在治疗由TNF-alpha或PDE4介导的疾病或疾病中的使用方法，包括但不限于类风湿关节炎。
• Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
  申请人：Mjalli M.M. Adnan

  公开号：US20070219235A1

  公开（公告）日：2007-09-20

  The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.

  本发明涉及用于治疗癌症的化合物和方法。该发明提供了抑制极化子激酶的化合物，包含抑制极化子激酶的化合物的制药组合物，以及使用本发明的化合物或包含本发明化合物的制药组合物治疗癌症的方法。
• Substituted bicyclic quinazolin-4-ylamine derivatives
  申请人：Bakthavatchalam Rajagopal

  公开号：US20070105865A1

  公开（公告）日：2007-05-10

  Substituted bicyclic quinazolin-4-ylamine derivatives are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  本发明提供了取代的二环喹唑啉-4-胺衍生物。这些化合物是配体，可用于体内或体外调节特定受体活性，并在治疗与人类、家畜伴侣动物和家畜动物中的病理性受体激活相关的疾病方面特别有用。还提供了用于治疗此类疾病的制药组合物和方法，以及用于受体定位研究的此类配体的使用方法。
• CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES
  申请人：Blum Charles A.

  公开号：US20100008866A1

  公开（公告）日：2010-01-14

  Cis-cyclohexyl substituted pyrimidinone derivatives are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  本文提供了Cis-环己基取代嘧啶酮衍生物，其化学式为：其中变量如本文所述。这些化合物是配体，可用于体内或体外调节特定受体的活性，并且在治疗与人类、家养伴侣动物和家畜动物的病理受体激活相关的情况方面特别有用。本文还提供了用于治疗此类疾病的制药组合物和方法，以及用于受体定位研究的配体的使用方法。